CIK 0001785530
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Werewolf Therapeutics, Inc.
Sign in to watch- Ticker
- HOWL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 823523180
- Phone
- +1 617-952-0555
- Business address
- 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-03 | HICKLIN DANIEL J | Grant or award · Stock Option (right to buy) | +295,500 | 295,500 | ||
| 2023-01-03 | Lubman Ellen Chief Business Officer | Grant or award · Stock Option (right to buy) | +86,200 | 86,200 | ||
| 2023-01-03 | Seidel-Dugan Cynthia Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +115,900 | 115,900 | ||
| 2023-01-03 | Karunatilake Chulani Chief Technology Officer | Grant or award · Stock Option (right to buy) | +103,600 | 103,600 | ||
| 2023-01-03 | Trost Timothy W. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +102,800 | 102,800 | ||
| 2023-01-03 | Leonard Reid Chief Operating Officer | Grant or award · Stock Option (right to buy) | +93,600 | 93,600 | ||
| 2023-01-03 | Isaacs Randi Chief Medical Officer | Grant or award · Stock Option (right to buy) | +103,300 | 103,300 | ||
| 2022-06-01 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +11,600 | 11,600 | ||
| 2022-06-01 | EVNIN LUKE Director | Grant or award · Stock Option (right to buy) | +11,600 | 11,600 | ||
| 2022-06-01 | DiRocco Derek Director | Grant or award · Stock Option (right to buy) | +11,600 | 11,600 | ||
| 2022-06-01 | Morrison Briggs Director | Grant or award · Stock Option (right to buy) | +11,600 | 11,600 | ||
| 2022-06-01 | Karunatilake Chulani Chief Technology Officer | Grant or award · Stock Option (right to buy) | +136,000 | 136,000 | ||
| 2022-06-01 | Lazarus Alon Director | Grant or award · Stock Option (right to buy) | +11,600 | 11,600 | ||
| 2022-06-01 | Sherman Michael A. Director | Grant or award · Stock Option (right to buy) | +11,600 | 11,600 | ||
| 2022-06-01 | Chatterjee Meeta Director | Grant or award · Stock Option (right to buy) | +7,733 | 7,733 | ||
| 2022-01-12 | Seidel-Dugan Cynthia Chief Scientific Officer | Exercise or conversion | +24,199 | $1.56 | $38K | 149,356 |
| 2022-01-12 | Seidel-Dugan Cynthia Chief Scientific Officer | Exercise or conversion | +15,532 | $4.77 | $74K | 164,888 |
| 2022-01-12 | Seidel-Dugan Cynthia Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −24,199 | 36,937 | ||
| 2022-01-12 | Seidel-Dugan Cynthia Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −15,532 | 83,631 | ||
| 2022-01-06 | Isaacs Randi Chief Medical Officer | Grant or award · Stock Option (right to buy) | +79,516 | 79,516 |
Page 12 of 17 · 335 trades